I-PRESERVE TrialIrbesartan in heart failure with preserved EF.pptVIP

Subject Accrual by Region/CountryAll Randomized Subjects (N=4128) I-PRESERVE: Baseline Characteristics (i) I-PRESERVE: Baseline Characteristics (ii) I-PRESERVE: Baseline Treatments Primary Outcome with Component Events Secondary Outcomes Discontinuations and Adverse Events EU member states as of Jan 1, 2007 I-PRESERVE TrialIrbesartan in heart failure with preserved EF Co-PIs: Peter Carson and Barry Massie Executive Committee M. Komajda, R. McKelvie, J. McMurray, M. Zile, C. Staiger, A. Ptaszynska On behalf of the I-PRESERVE Committees and Investigators Presenter Disclosure Information The following relationships exist related to this presentation: P Carson: Bristol-Myers Squibb - sanofi aventis consulting fees B Massie: Bristol-Myers Squibb - sanofi aventis grant support, consulting fees J McMurray: Bristol-Myers Squibb funds for Glasgow University M Komajda: Bristol-Myers Squibb consulting fees R McKelvie: Bristol-Myers Squibb - sanofi aventis consulting fees M Zile: Bristol-Myers Squibb - sanofi aventis consulting fees C Staiger: sanofi aventis employee and holds stock options A Ptaszynska: Bristol-Myers Squibb employee and holds stock options I-PRESERVE was sponsored by Bristol-Myers Squibb and sanofi aventis CO-PRINCIPALINVESTIGATORS P Carson B Massie EXECUTIVE COMMITTEE J McMurray, M Zile, M Komajda, A Ptaszynska, R McKelvie, C Staiger INTERNATIONAL STEERING COMMITTEE R Diaz, H Krum, D Kitzman, C OConnor, J Vanhaecke, E Tinoco Mesquita, J Hradec, L K?ber, Y Juilliere, R Dietz, D Cokkinos, I édes, K McDonald, L Tavazzi, C Sanchez Diaz, J Otterstad, P Ponikowski, R Seabra Gomes, V Mareev, A Dalby, J González-Juanatey, U Dahlstr?m, F Follath ADJUDICATION COMMITTEE Michael Zile, William Gaasch, William Little, Inder Anand, John Teerlink, Michael White, Markus Haass, Jose Lopez-Sendon, Alan Miller DATA SAFETY MONITORING COMMITTEE Sydney Goldstein, Jay Cohn, Desmond Julian, Alain Leizorovicz, James Neaton I-P